PlainPharmaWatch

CMS Open Payments · Program Year 2024

HEMA Biologics, LLC

HEMA Biologics, LLC reported $476,310.80 across General Payments, Research, and Ownership to 430 physicians and teaching hospitals across 454 transactions.

See the rankings → How this is sourced
$476.3K
All-tracks total
454
Transactions
430
Recipients
−$384.0K
General Payments vs PY2023

HEMA Biologics, LLC reported $476,310.80 across all CMS Open Payments tracks (General + Research + Ownership) to 430 physicians and teaching hospitals in Program Year 2024 - ranking #775 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $276,535.80, averaging $1.1K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer hema-biologics-llc HEMA Biologics, LLC

$476.3K · #775/1,925 · 0.0% industry · PY2024

  • TOT $476.3K
  • RANK #775
  • SHARE 0.0%
  • TXN 454
  • RCP 430
  • CAT 6
  • GEN $276.5K
  • ΔGEN −$384.0K
  • TOP1 14.8%
  • PY 2024

Volume peers

Nearest volume peer: ImClone Systems, LLC ($476.4K)

Gentuity, LLC$477.9KImClone Systems, LLC$476.4KHEMA Biologics, LLC (this)$476.3KMonteris Medical Corporation$475.8KPrenosis Inc.$474.5K
All-tracks payment totals near HEMA Biologics, LLC (CMS Open Payments PY2024)

HEMA Biologics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

HEMA Biologics, LLC's CMS-reported General Payments decreased by $384.0K (−58.1%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: HEMA BIOLOGICS, LLCPY2023: HEMA BIOLOGICS, LLCPY2024: HEMA Biologics, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$660.5KPY2024$276.5K
PY2023
$660,529.56
PY2024
$276,535.80

What the Data Shows for HEMA Biologics, LLC

In Program Year 2024, HEMA Biologics, LLC reported $476,310.80 in payments to 430 physicians and teaching hospitals across 454 individual transactions, an average of $1.0K per transaction and $1.1K per recipient. That total places HEMA Biologics, LLC at rank #775 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $179.8K across 40 transactions, 65.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads HEMA Biologics, LLC's 6-category general-payment breakdown at $179.8K, 65.0% of the reported total.

HEMA Biologics, LLC reports 6 general-payment categories - the top three are Consulting Fee (65.0%), Compensation for Services Other Than Consulting (15.7%), and Travel and Lodging (11.8%). The remaining 3 categories make up 7.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How HEMA Biologics, LLC divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$179.8K2. Compensation for Services…$43.5K3. Travel and Lodging$32.6K4. Food and Beverage$14.2K5. Honoraria$6.5K6. Education$32.94
Payment Type Amount Transactions
Consulting Fee $179.8K 40
Compensation for Services Other Than Consulting $43.5K 16
Travel and Lodging $32.6K 147
Food and Beverage $14.2K 222
Honoraria $6.5K 3
Education $32.94 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $135,086.89 (48.8%) of $276,535.80 in this company's General Payments records across 88 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for HEMA Biologics, LLC

The five named recipients with the highest reported General Payments from this company

Doris Quon$41.0KGuy Young$36.9KMaissaa Janbain$29.1KMiguel Escobar$14.1KSteven Pipe$13.9K
  1. 1

    Doris Quon

    $41,043.72 across 55 reported transactions

  2. 2

    Guy Young

    $36,883.68 across 48 reported transactions

  3. 3

    Maissaa Janbain

    $29,120.08 across 15 reported transactions

  4. 4

    Miguel Escobar

    $14,146.62 across 14 reported transactions

  5. 5

    Steven Pipe

    $13,892.79 across 15 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as HEMA Biologics, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about HEMA Biologics, LLC.

Precision Spine, Inc.

HHI 690

Kuraray America Inc.

HHI 690

BK Medical Holding Company Inc.

HHI 693

Ascendis Pharma Inc

HHI 686

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with HEMA Biologics, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download HEMA Biologics, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.